Company: BIAF
Filing Date: 2025-06-27
Form Type: POS AM
Source: 0001641172-25-016927
Chunk: 90

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-06-27
Form: POS AM
Chunk 90
---
 the descriptions relate only to the periods listed, which may not be indicative of our future financial outcomes. In addition to historical information, this discussion contains forward-looking statements that involve risks, uncertainties, and assumptions that could cause the Company’s financial results to differ materially from management’s expectations. Factors that could cause such differences are discussed in the “Cautionary Note Regarding Forward-Looking Statements” section of this prospectus and in the “Risk Factors” in this prospectus.

Our MD&A is organized as follows:

| ● 
 ● | Company                                                                                                                       
 Overview – Discussion of our business plan and strategy to provide context for the remainder of the MD&A.                     
 Results                                                                                                                       
 of Operations – Analysis of our financial results comparing the three months ended March 31, 2025, to                         
 the comparable period in 2024 as well as the year ended December 31, 2024, to the year ended December 31, 2023.               |
|:--|:------------------------------------------------------------------------------------------------------------------------------|
| ● | Liquidity                                                                                                                     
 and Capital Resources – Analysis of changes in our cash flows and discussion of our financial condition and potential sources 
 of liquidity.                                                                                                                 |
| ● | Critical                                                                                                                      
 Accounting Estimates – Accounting estimates are those estimates made in accordance with U.S. generally accepted               
 accounting principles (“GAAP”) that we believe are important to understanding the assumptions and judgments incorporated      
 in our reported financial results and forecasts.                                                                              |

Company Overview

Business

We develop noninvasive diagnostics to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis developed by machine learning, a form of artificial intelligence (“AI”). One of our diagnostic tests analyzes cell populations, including cancer and cancer-related cells, that are indicative of a specific diseased state.

Our diagnostic test, CyPath ®Lung, addresses the need for noninvasive detection of early-stage lung cancer. Lung cancer is the leading cause of cancer-related deaths worldwide. Physicians order CyPath ®Lung to assist in their assessment of patients who are at high risk for lung cancer. The CyPath ®Lung test enables physicians to more confidently identify patients who will likely benefit from timely intervention and more invasive follow-up procedures and those who are likely without lung cancer and should continue routine screening. CyPath ®Lung has the potential to increase overall diagnostic accuracy of lung cancer, which could lead to increased survival, fewer unnecessary invasive procedures, reduced patient anxiety, and lower medical costs.

Commercial laboratory services, including CyPath ®Lung, are